Dow Jones

43 948,98

1,25%

DAX

Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

S'inscrire

Accueil
Investir
Actions
Etats-Unis
NASDAQ
Acasti Pharma Inc (ACST)
Acasti Pharma Inc (ACST) Actualités

ACST

Acasti Pharma (ACST)

Acasti Pharma Inc

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:NASDAQ:ACST

1 2 3 4 5 6 7 8 Suivant >>

Date	Heure	Source	Titre	Symbole	Société
28/10/2024	13h22	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ACST	Acasti Pharma Inc
16/10/2024	06h15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:ACST	Acasti Pharma Inc
08/10/2024	13h22	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:ACST	Acasti Pharma Inc
08/10/2024	13h16	Edgar (US Regulatory)	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments	NASDAQ:ACST	Acasti Pharma Inc
08/10/2024	13h15	Edgar (US Regulatory)	Form POS AM - Post-Effective amendments for registration statement	NASDAQ:ACST	Acasti Pharma Inc
06/09/2024	22h07	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:ACST	Acasti Pharma Inc
09/08/2024	13h30	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ACST	Acasti Pharma Inc
07/08/2024	22h14	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:ACST	Acasti Pharma Inc
31/07/2024	13h22	Edgar (US Regulatory)	Form S-4/A - Registration of securities, business combinations: [Amend]	NASDAQ:ACST	Acasti Pharma Inc
11/07/2024	17h16	Edgar (US Regulatory)	Form 3/A - Initial statement of beneficial ownership of securities: [Amend]	NASDAQ:ACST	Acasti Pharma Inc
11/07/2024	03h10	Edgar (US Regulatory)	Form SC 13G - Statement of Beneficial Ownership by Certain Investors	NASDAQ:ACST	Acasti Pharma Inc
10/07/2024	02h29	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:ACST	Acasti Pharma Inc
10/05/2024	22h11	Edgar (US Regulatory)	Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]	NASDAQ:ACST	Acasti Pharma Inc
09/05/2024	01h19	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ACST	Acasti Pharma Inc
10/10/2023	13h40	Edgar (US Regulatory)	Form D - Notice of Exempt Offering of Securities	NASDAQ:ACST	Acasti Pharma Inc
06/10/2023	22h30	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:ACST	Acasti Pharma Inc
25/08/2023	22h15	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:ACST	Acasti Pharma Inc
10/07/2023	15h00	PR Newswire (US)	Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients	NASDAQ:ACST	Acasti Pharma Inc
07/07/2023	14h00	PR Newswire (US)	Acasti Pharma Announces 1-for-6 Reverse Stock Split	NASDAQ:ACST	Acasti Pharma Inc
05/07/2023	15h00	PR Newswire (US)	Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023	NASDAQ:ACST	Acasti Pharma Inc
23/06/2023	13h02	Edgar (US Regulatory)	Annual Report (10-k)	NASDAQ:ACST	Acasti Pharma Inc
23/06/2023	13h00	PR Newswire (US)	Acasti Pharma Reports Fiscal Year 2023 Operational Results	NASDAQ:ACST	Acasti Pharma Inc
22/06/2023	15h00	PR Newswire (US)	Acasti Announces Appointment of New Scientific Advisory Board Members	NASDAQ:ACST	Acasti Pharma Inc
26/05/2023	21h07	Edgar (US Regulatory)	Initial Statement of Beneficial Ownership (3)	NASDAQ:ACST	Acasti Pharma Inc
17/05/2023	15h00	PR Newswire (US)	Acasti to Participate in the Lytham Partners Spring 2023 Investor Conference	NASDAQ:ACST	Acasti Pharma Inc
08/05/2023	13h00	PR Newswire (US)	Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025	NASDAQ:ACST	Acasti Pharma Inc
05/04/2023	23h01	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:ACST	Acasti Pharma Inc
04/04/2023	14h01	PR Newswire (US)	Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND	NASDAQ:ACST	Acasti Pharma Inc
04/04/2023	14h00	PR Newswire (US)	Acasti Announces Appointment of Prashant Kohli as CEO	NASDAQ:ACST	Acasti Pharma Inc
30/03/2023	14h30	PR Newswire (US)	Acasti Pharma Inc. Announces the Resignation of a Director	NASDAQ:ACST	Acasti Pharma Inc